IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 86 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 1.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,495,920 | -32.6% | 2,746,356 | +4.2% | 0.00% | -50.0% |
| Q2 2023 | $18,552,420 | +46.7% | 2,635,287 | +27.3% | 0.00% | 0.0% |
| Q1 2023 | $12,643,000 | +84587.5% | 2,069,371 | -11.4% | 0.00% | 0.0% |
| Q4 2022 | $14,929 | -99.9% | 2,336,120 | +10.5% | 0.00% | -33.3% |
| Q3 2022 | $20,246,000 | -10.2% | 2,113,278 | +3.5% | 0.00% | 0.0% |
| Q2 2022 | $22,541,000 | -27.0% | 2,041,669 | +10.1% | 0.00% | -25.0% |
| Q1 2022 | $30,865,000 | -19.9% | 1,853,733 | -8.1% | 0.00% | 0.0% |
| Q4 2021 | $38,513,000 | -4.7% | 2,017,431 | +23.1% | 0.00% | -20.0% |
| Q3 2021 | $40,412,000 | +9.8% | 1,638,736 | +15.8% | 0.01% | +25.0% |
| Q2 2021 | $36,819,000 | -13.4% | 1,415,007 | +5.4% | 0.00% | -33.3% |
| Q1 2021 | $42,514,000 | -2.8% | 1,342,809 | +42.4% | 0.01% | 0.0% |
| Q4 2020 | $43,756,000 | +92.6% | 943,013 | +34.1% | 0.01% | +50.0% |
| Q3 2020 | $22,722,000 | +32.2% | 703,472 | +12.3% | 0.00% | +33.3% |
| Q2 2020 | $17,194,000 | +2.9% | 626,379 | +12.2% | 0.00% | -25.0% |
| Q1 2020 | $16,709,000 | +12.7% | 558,157 | +4.2% | 0.00% | +33.3% |
| Q4 2019 | $14,831,000 | +72.0% | 535,762 | +13.1% | 0.00% | +50.0% |
| Q3 2019 | $8,622,000 | -17.8% | 473,697 | +2.1% | 0.00% | 0.0% |
| Q2 2019 | $10,486,000 | +148.0% | 464,176 | +4.4% | 0.00% | +100.0% |
| Q1 2019 | $4,228,000 | +6.3% | 444,644 | -1.1% | 0.00% | 0.0% |
| Q4 2018 | $3,977,000 | -17.4% | 449,369 | +4.9% | 0.00% | 0.0% |
| Q3 2018 | $4,817,000 | -13.7% | 428,232 | -1.8% | 0.00% | 0.0% |
| Q2 2018 | $5,580,000 | -35.3% | 435,886 | -14.5% | 0.00% | -50.0% |
| Q1 2018 | $8,619,000 | -14.8% | 509,988 | -59.7% | 0.00% | 0.0% |
| Q4 2017 | $10,113,000 | -28.1% | 1,264,110 | -29.0% | 0.00% | -33.3% |
| Q3 2017 | $14,059,000 | +75.6% | 1,779,700 | +63.4% | 0.00% | +50.0% |
| Q2 2017 | $8,006,000 | – | 1,089,173 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 565,890 | $26,257,000 | 9.39% |
| Consonance Capital Management LP | 1,710,803 | $79,381,000 | 7.41% |
| GREAT POINT PARTNERS LLC | 917,427 | $42,569,000 | 6.91% |
| Avoro Capital Advisors LLC | 7,500,000 | $348,000,000 | 5.99% |
| Ghost Tree Capital, LLC | 500,000 | $23,200,000 | 5.17% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $60,923,000 | 4.69% |
| Perceptive Advisors | 9,166,304 | $425,316,000 | 4.56% |
| Ally Bridge Group (NY) LLC | 360,000 | $16,704,000 | 2.86% |
| Orbimed Advisors | 6,645,100 | $308,333,000 | 2.70% |
| ACUTA CAPITAL PARTNERS, LLC | 164,800 | $7,647,000 | 2.08% |